This was the stock's third consecutive day of gains.

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the ...

We recently compiled a list of the 10 Best High-Yield Dividend Stocks To Invest In. In this article, we are going to take a ...

We came across a bullish thesis on Bristol-Myers Squibb Company (BMY) on Disruptive analytics’ Substack by Magnus Ofstad. In ...

Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $57.04 which represents a slight increase of $0.75 or 1.33% from the prior close of $56.29. The stock opened at $56.63 and ...

Bristol Myers Squibb CEO Chris Boerner described Cobenfy, a new drug to treat schizophrenia and may also help with bipolar ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Ameritas Advisory Services LLC increased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 9.4% in ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...

To get a sense of who is truly in control of Bristol-Myers Squibb Company ( NYSE:BMY ), it is important to understand the ...

Bristol Myers Squibb believes Alzheimer's treatment is the largest potential market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars ...